ALFA Finder| Management target | Revenue 20.0% Q1FY22 to Q1FY27 |
|---|
| Revenue growth | 24% YoY Consolidated |
|---|---|
| Margins | EBITDA margin up 226bps to 32% |
| Demand visibility | Strong growth in pathology vials (+22% YoY) |
| Management confidence | High; citing 'Routine to Remarkable' strategy |
Growth
Pathology revenue grew 26% YoY; standalone revenue at 226 Cr. EBITDA grew 34% YoY with margins improving to 32%.
Outlook
Expanding specialty offerings (Genomics, NIPT) and strengthening B2B franchise network. Capex of ~250 Cr over the last 5 years.
Risks
Radiology revenue declined 4% YoY due to strategic exits from non-profitable centers.
Last quarter's promises, checked
Delivered
- Guided mid-to-high teens revenue growth → delivered 24% (= BEAT)
- Guided 500 new franchisees per quarter → delivered 900+ (= BEAT)
- Guided 40 labs → delivered 44 labs (= BEAT)
Partly delivered
- Guided radiology consolidation for bottom-line improvement → revenue still declining 4% (= PARTIAL)
Missed
- Guided 34% normalized EBITDA margin → delivered 32% (= MISS)
Investor Presentation filed with BSE, NSE: THYROCARE. Summary written with AI assistance from the document.
Thyrocare Technologies Ltd: key numbers
- Share price
- ₹488.95
- Market cap
- ₹7,792 Cr
- Revenue (annual)
- ₹829.0 Cr
- Net profit (annual)
- ₹163.0 Cr
- P/E (TTM)
- 54.0×Sector 54.5×
- Promoter holding
- 51.02%-9.90% QoQ
- FII holding
- 9.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Thyrocare Technologies Ltd
All →Thyrocare Technologies Other Announcement
Designated person Rahul Guha bought 2,121 Thyrocare shares via market purchase on November 6, 2026, worth ₹0.10 Crore. Post-trade holding is 200,859 shares.
- Value
- ₹0.10 Cr
Thyrocare Technologies Employee Stock Options
Thyrocare allotted 1,94,289 equity shares under its Employee Stock Option Scheme. The allotment lifts paid-up capital to Rs 159.36 crore.
Thyrocare Technologies Management Change
Thyrocare Technologies' Chief Scientific Officer, Dr. Preet Kaur, resigns effective November 6, 2026. The company is identifying a replacement and will disclose details later.
Thyrocare Technologies Other Announcement
Thyrocare disclosed NSE market purchases by an immediate relative and a KMP on 2 November 2026. Combined consideration is about Rs 0.11 Crore, with no promoter involved.
- Value
- ₹0.11 Cr
Thyrocare Technologies Merger & Restructuring Worth ₹141.4 Cr
Thyrocare agreed to sell its entire stake in subsidiary Nueclear Healthcare to Trovera. The consideration is about Rs 141.40 Crore, including preference shares and cash.
- Value
- ₹141.4 Cr
Thyrocare Technologies Annual General Meeting
Thyrocare Technologies reported postal ballot voting results approving the purchase of land and building from, and divestment of its entire shareholding in, Nueclear Healthcare Limited.